Soleno Shaken By FDA Demand For Second DCCR Phase III Trial In PWS
The Biotech Adequately Funded So Likely To Comply
The US FDA has asked Soleno to conduct another Phase III Study evaluating its chief asset in Prader-Willi syndrome patients prior to any NDA submission, rattling investors and clouding the company’s prospects.
